Search

Nogapendekin alfa

It is one of the active ingredients in Anktiva, a combination product also containing [inbakicept], where a single inbakicept is complexed with two nogapendekin alfa components. … [L50592] This combination product was approved by the FDA on April 22, 2024, for the treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without

Dalfampridine

Dalfampridine is a potassium channel blocker used to help multiple sclerosis patients walk. This is the first drug that was specifically approved to help with mobility in these patients. … FDA approved on January 22, 2010.

Oxazepam

Oxazepam is an intermediate-acting, 3-hydroxybenzodiazepine used in the treatment of alcohol withdrawal and anxiety disorders. … as compared to other benzodiazepines, and is likely owing in part to oxazepam's relatively simple metabolism.

Esmirtazapine

Merck has terminated its internal clinical development program for esmirtazapine as of March 2010. … Esmirtazapine is the (S)-(+)-enantiomer of mirtazapine and possesses similar overall pharmacology.

Vonoprazan

Unlike proton-pump inhibitors, PCABs are not affected by CYP2C19 genetic polymorphisms and do not require acid-resistant formulations. … [A253702] In May 2022, the FDA approved the use of vonoprazan in a co-packaged product containing amoxicillin and clarithromycin for the treatment of _H. pylori_ infection.

Bordetella pertussis pertactin antigen (formaldehyde inactivated)

Avacopan

by the presence of ANCAs in the serum. … two main forms of ANCA-associated vasculitis - in combination with [rituximab] or [cyclophosphamide].

Dequalinium

[A249255] First used as an antiseptic and disinfectant in the 1950s, dequalinium is still found in various OTC products to treat conditions of oral infections and inflammation. … [A249255] It is also used in vaginal tablets to treat bacterial vaginosis.[L42190]

Levoketoconazole

Still, toxicity has limited its use, notably hepatic toxicity and a tendency to prolong the QT interval.[A244083] Levoketoconazole is one of two enantiomers present in racemic [ketoconazole]. … changes in body composition, neuropsychiatric effects, changes in blood pressure and chemistry, and opportunistic infections.

Lisdexamfetamine

Lisdexamfetamine is a prodrug of [dextroamphetamine], a central nervous system stimulant known as d-amphetamine,[A40246] covalently attached to the naturally occurring amino acid L-lysine. … [A2230] Lisdexamfetamine is the first chemically formulated prodrug stimulant [A40246] and was first approved by the FDA in April 2008.[A2230] It was also approved by Health Canada in February 2009.